The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Current Challenges and Opportunities in Treating Glioblastoma
Open accessAbstract
that are overexpressed in a subpopulation of GBM patients and correlate with poor survival outcomes. Importantly, nine of these genes exhibit higher expression in GBM versus low-grade glioma and may be involved in disease progression. In this review, we discuss these proteins in the context of GBM disease progression. We also conducted computational multi-parameter optimization to assess the blood-brain barrier (BBB) permeability of small molecules in clinical trials for GBM treatment. Drug delivery in the context of GBM is particularly challenging because the BBB hinders small molecule transport. Therefore, we discuss novel drug delivery methods, including nanoparticles and prodrugs. Given the aggressive nature of GBM and the complexity of targeting the central nervous system, effective treatment options are a major unmet medical need. Identification and validation of biomarkers and drug targets associated with GBM disease progression present an exciting opportunity to improve treatment of this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–238 of 238
Chen, J.-R., Xu, H., Yao, Y., & Qin, Z.-Y. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12401 · Cited by 38
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma
Schäfer, N., Gielen, G. H., Kebir, S., Wieland, A., Till, A., Mack, F., Schaub, C., Tzaridis, T., Reinartz, R., Nießen, M., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2161-0 · Cited by 38
Annexin 2A sustains glioblastoma cell dissemination and proliferation
Maule, F., Bresolin, S., Rampazzo, E., Boso, D., Puppa, A. D., Esposito, G., Porcù, E., Mitola, S. M. F., Lombardi, G., Accordi, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10565 · Cited by 38
Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2
Witt, D., Burfeind, P., Hardenberg, S. V., Opitz, L., Salinas, G., Bremmer, F., Schweyer, S., Thelen, P., Neesen, J., & Kaulfuß, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt019 · Cited by 37
Structural Studies Revealed Active Site Distortions of Human Furin by a Small Molecule Inhibitor
Dahms, S. O., Jiao, G., & Than, M. E. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00633 · Cited by 37
Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer
Teng, C., & Zheng, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.6714 · Cited by 37
Muranaka, H., Hayashi, A., Minami, K., Kitajima, S., Kohno, S., Nishimoto, Y., Nagatani, N., Suzuki, M., Kulathunga, L. A. N., Sasaki, N., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.51 · Cited by 36
Semaphorin–plexin signalling genes associated with human breast tumourigenesis
Gabrovska, P. N., Smith, R. A., Tiang, T., Weinstein, S. R., Haupt, L. M., & Griffiths, L. R. (2011) · Gene · doi:10.1016/j.gene.2011.08.024 · Cited by 35
Wu, J., Li, L., Jiang, G., Zhan, H., & Wang, N. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3729 · Cited by 34
Novel transcriptional regulation of VEGF in inflammatory processes
Tang, X., Yu, Y., Yuan, H., You, J., Burkatovskaya, M., & Amar, S. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12020 · Cited by 33
SAMSN1 Is Highly Expressed and Associated with a Poor Survival in Glioblastoma Multiforme
Yan, Y., Zhang, L., Xu, T., Zhou, J., Qin, R., Chen, C., Zou, Y., Fu, D., Hu, G., Chen, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081905 · Cited by 33
Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines.
Wu, W. K. K., Tse, T. T. M., Sung, J. J. �., Li, Z. J., Yu, L., & Cho, C. H. (2009) · PubMed · Cited by 32
Yu, X., Feng, L., Liu, D., Zhang, L., Wu, B., Jiang, W., Han, Z., & Cheng, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7416 · Cited by 32
Gene knockdown of CENPA reduces sphere forming ability and stemness of glioblastoma initiating cells
Behnan, J., Grieg, Z., Joel, M., Ramsnes, I., & Stangeland, B. (2016) · Neuroepigenetics · doi:10.1016/j.nepig.2016.08.002 · Cited by 31
He, X., Ping, J., & Wen, D.-G. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4908 · Cited by 30
Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM)
Demeure, K., Fack, F., Duriez, E., Tiemann, K., Bernard, A., Golebiewska, A., Bougnaud, S., Bjerkvig, R., Domon, B., & Niclou, S. P. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.052423 · Cited by 29
Follicular dendritic cell secreted protein FDC-SP controls IgA production
Hou, S., Landego, I., Jayachandran, N., Miller, A., Gibson, I. W., Ambrose, C. M., & Marshall, A. J. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.113 · Cited by 28
Proteomic Analysis of Glioma Chemoresistance
Suk, K. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362733 · Cited by 28
Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma
Szczurek, E., Misra, N., & Vingron, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28235 · Cited by 27
Alonso, M. M., García-Moure, M., González-Huarriz, M., Marigil, M., Hernández-Alcoceba, R., Buñales, M., Hervás, S., Pérez‐Larraya, J. G., Gomez‐Manzano, C., Fueyo-Margareto, J., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct027 · Cited by 27
What Is Wrong with Clinical Proteomics?
Meo, A. D., Diamandis, E. P., Rodriguez, H., Hoofnagle, A. N., Ioannidis, J. P. A., & Lopez, M. F. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.225185 · Cited by 24
Li, Y., Zhou, Y., Qi, B., Gong, T., Sun, X., Fu, Y. S., & Zhang, Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500352p · Cited by 24
Tang, X., Molina, M., & Amar, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1600 · Cited by 23
Sleeping Beauty Mouse Models Identify Candidate Genes Involved in Gliomagenesis
Vyazunova, I., Maklakova, V. I., Berman, S., De, I., Steffen, M. D., Hong, W. S., Lincoln, H., Morrissy, A. S., Taylor, M. D., Akagi, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113489 · Cited by 22
Regulation of the actin cytoskeleton by the Ndel1-Tara complex is critical for cell migration
Hong, J., Kwak, Y., Woo, Y. S., Park, C., Lee, S., Lee, H., Park, S. J., Park, S. J., Suh, Y., Suh, B. K., et al. (2016) · Scientific Reports · doi:10.1038/srep31827 · Cited by 22
Small cell lung cancer growth is inhibited by miR-342 through its effect of the target gene IA-2
Xu, H., Cai, T., Carmona, G. N., Abuhatzira, L., & Notkins, A. L. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1036-0 · Cited by 20
Ventura, E., Weller, M., & Burghardt, I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601176 · Cited by 18
Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors
Ferreira, W. A. S., Araújo, M. D., Anselmo, N. P., de Oliveira, E. H. C., Brito, J. R. N., Burbano, R. M. R., Harada, M. L., & Borges, B. D. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137259 · Cited by 17
Scopine as a Novel Brain-Targeting Moiety Enhances the Brain Uptake of Chlorambucil
Wang, X., Li, J., Xu, C., Li, Y., Gong, T., Sun, X., Fu, Y. S., He, Q., & Zhang, Z. (2014) · Bioconjugate Chemistry · doi:10.1021/bc5004108 · Cited by 17
Palanichamy, K., Patel, D., Jacob, J. R., Litzenberg, K. T., Gordon, N., Acus, K., Noda, S., & Chakravarti, A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0429 · Cited by 17
ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response
Nikolos, F., Thomas, C. G., Bado, I., & Gustafsson, J.-Α. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0201 · Cited by 17
Robinson, C. G., Palomo, J. M., Rahmathulla, G., McGraw, M., Donze, J. R., Liu, L., & Vogelbaum, M. A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605792 · Cited by 15
Prókai-Tátrai, K., Szarka, S., & Nguyen, V. (2011) · Pharmaceutica Analytica Acta · doi:10.4172/2153-2435.s7-002 · Cited by 14
Identification of Prostate Cancer LncRNAs by RNA-Seq
Hu, C., Gan, P., Zhang, R., Xue, J.-X., & Ran, L. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.21.9439 · Cited by 14
LITAF is a potential tumor suppressor in pancreatic cancer
Zhou, Y., Huang, J., Yu, X., Jiang, X., Shi, Y., Weng, Y., Kuai, Y., Lei, L., Ren, G., Feng, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23220 · Cited by 14
Reduced QSOX1 enhances radioresistance in nasopharyngeal carcinoma
Zhou, L., Chen, H., Qu, S., Li, L., Zhao, W., Liang, Z., Yu, B., Chen, K.-H., Lu, Q., Lin, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23227 · Cited by 13
Godoy, P. R. D. V., Montaldi, A. P., & Sakamoto‐Hojo, E. T. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5877 · Cited by 12
Animal Models in Glioblastoma: Use in Biology and Developing Therapeutic Strategies
Schuhmacher, A. J., & Squatrito, M. (2017) · Current cancer research · doi:10.1007/978-3-319-56820-1_9 · Cited by 4
Cited by
Artificial intelligence for multimodal data integration in oncology
Lipkova, J., Chen, R. J., Chen, B., Lu, M. Y., Barbieri, M., Shao, D., Vaidya, A. J., Chen, C., Zhuang, L., Williamson, D. F. K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.012 · Cited by 777
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., & Hatley, R. J. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 540
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 373
Metadata
- Authors
- Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 70
- Issue
- 3
- Pages
- 412-445
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2800469107
- Cited by
- 849
- References
- 238
- FWCI
- 38.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.